Compare 8x8 Inc (EGHT) vs Summit Therapeutics Inc (SMMT) Price & Performance

EGHT (8x8, Inc.) trades at $2.035, down 6.22% on the day. The stock shows a bullish technical signal from moving averages, though oscillators are neutral. Fundamentally, the company reported a net loss of $27.21M for 2025 but has beaten EPS estimates for three consecutive quarters. Recent news highlights product innovation with AI Routing and Pulse solutions, and the company was named a 2026 MetriStar Top Provider for CPaaS. Revenue grew to $715.07M in 2025, with a forecasted return to profitability in 2026.

The outlook hinges on the company's transition to profitability, projected for 2026 with a net profit of $2M. Investment opportunities include continued revenue growth, successful execution of new AI-driven products, and cost discipline. Key risks are the high P/E ratio of 197, significant long-term debt of $338.37M, and the challenge of sustaining recent earnings beats. Analyst sentiment is mixed but leans positive, with 39% Buy ratings.

Summit Therapeutics (SMMT) trades at $13.90, down 10.15% today, reflecting market reaction to mixed earnings and high volatility. The technical picture is bearish with weak moving averages, while fundamentals show significant losses with a net income of -$1.08B in 2025 and negative ROE/ROA. Recent news includes a $105M divestiture of ridinilazole to Biossil, sharpening focus on oncology, and upcoming Q2 2026 results on July 23, 2026.

Outlook hinges on clinical success of ivonescimab, with a bullish analyst consensus (66.7% buy ratings) and $15.57 price target suggesting 12% upside. Key risks include binary drug trial outcomes, cash burn from negative operating cash flow, and high short interest creating volatility. Investors face a high-risk, catalyst-driven opportunity dependent on pipeline execution.